Neogen (NASDAQ:NEOG) Shares Gap Up - Here's Why

Key Points

• Neogen shares opened higher, rising from a prior close of $11.64 to $12.18 before trading near $11.99, a gain of roughly 1.7%.
• Zacks raised several longer-term EPS forecasts, including fiscal 2028 to $0.29 from $0.28, while one near-term forecast was cut. Neogen’s latest quarterly results also exceeded expectations, with EPS of $0.09 versus a $0.06 consensus and revenue of $225.3 million.
• Analyst sentiment is mixed: Piper Sandler upgraded the stock to overweight with a $14 target, but the broader consensus remains Hold with an average price target of $12.00. Institutional investors own approximately 96.7% of the shares.

Shares of Neogen Corporation (NASDAQ:NEOG - Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $11.64, but opened at $12.18. Neogen shares last traded at $11.9940, with a volume of 161,083 shares changing hands.

Trending Headlines about Neogen

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Zacks Research raised its fiscal 2028 EPS forecast for Neogen to $0.29 from $0.28. The firm also increased estimates for several periods, including Q2 2027 to $0.08 from $0.07, Q3 2027 to $0.06 from $0.05, and Q4 2027 to $0.07 from $0.06. These revisions suggest improving expectations for the company’s future profitability. MarketBeat Neogen analyst estimates
• Positive Sentiment: Zacks also lifted its Q3 2028 EPS estimate to $0.07 from $0.06 and its Q4 2028 estimate to $0.09 from $0.08. The current-year consensus remains $0.25 per share, while the higher fiscal 2028 outlook provides a longer-term earnings-growth narrative for investors. MarketBeat Neogen earnings estimates
• Neutral Sentiment: Reported short interest was listed at zero shares, producing a zero-day short-interest ratio. Because the figures appear inconsistent and provide no meaningful short-covering signal, the data is unlikely to be a reliable driver of the stock. MarketBeat Neogen short interest
• Negative Sentiment: An analyst price-target report cited a target of $11.67, which is below the stock’s recent trading level and could signal limited near-term upside. Analysts set Neogen price target
• Negative Sentiment: Zacks lowered its Q1 2028 EPS forecast to $0.05 from $0.06, partially offsetting the broader series of upward revisions. Neogen also continues to trade at a demanding valuation relative to current earnings, making execution and sustained profit growth important.

Analyst Ratings Changes

NEOG has been the subject of several analyst reports. Wall Street Zen upgraded shares of Neogen from a "hold" rating to a "buy" rating in a report on Saturday, May 9th. Weiss Ratings raised shares of Neogen from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, August 7th. Finally, Piper Sandler upgraded shares of Neogen from a "neutral" rating to an "overweight" rating and set a $14.00 price objective for the company in a research report on Wednesday. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Neogen has a consensus rating of "Hold" and an average price target of $12.00.

Neogen Trading Up 1.7%

The business has a fifty day moving average of $10.31 and a 200-day moving average of $9.84. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.91 and a current ratio of 3.82. The company has a market capitalization of $2.58 billion, a P/E ratio of -393.50, a PEG ratio of 4.58 and a beta of 1.77.

Neogen (NASDAQ:NEOG - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.03. Neogen had a negative net margin of 0.91% and a positive return on equity of 2.78%. The business had revenue of $225.30 million during the quarter, compared to the consensus estimate of $212.35 million. During the same quarter last year, the firm posted ($2.82) EPS. Neogen's revenue was down .1% compared to the same quarter last year. Analysts anticipate that Neogen Corporation will post 0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Neogen

Hedge funds and other institutional investors have recently made changes to their positions in the business. Nykredit A S acquired a new position in Neogen during the 2nd quarter valued at about $28,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Neogen in the second quarter worth approximately $34,000. UMB Bank n.a. raised its stake in shares of Neogen by 238.2% in the fourth quarter. UMB Bank n.a. now owns 6,422 shares of the company's stock worth $45,000 after purchasing an additional 4,523 shares during the last quarter. Hantz Financial Services Inc. raised its stake in shares of Neogen by 816.9% in the fourth quarter. Hantz Financial Services Inc. now owns 7,592 shares of the company's stock worth $53,000 after purchasing an additional 6,764 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Neogen by 3,158.4% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 8,309 shares of the company's stock valued at $58,000 after purchasing an additional 8,054 shares in the last quarter. 96.73% of the stock is owned by institutional investors.

About Neogen

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen's product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source